Roberto Pili
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Roberto Pili sits in the upper quartile of US sponsors by registered trial count (#3,661 of 15,742 sponsors by registered trial count).
Roberto Pili: 3 sponsored US clinical trials, none currently recruiting.
Roberto Pili sponsors 3 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 0 of these trials are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Renal Cell Carcinoma, with 1 trials.
Upper-quartile sponsor footprint
Roberto Pili sits in the upper quartile of the sponsor corpus (#3,661 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Indexed trials (enrollment closed)
3 total, page 1 of 1
High Dose IL 2 and Entinostat in RCC
NCT03501381
Study of Entinostat With Nivolumab Plus Ipilimumab in Previously Treated Renal Cell Carcinoma
NCT03552380
Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell Carcinoma
NCT03024437
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 2 |
Therapeutic Areas
How the Roberto Pili early-phase archive is shaped
3 indexed studies, none listed as recruiting (0% open).
Phase mix: 0 late (III/IV) vs 3 early (I/II) (early-phase heavy).
Top condition: Renal Cell Carcinoma (1 trial), 0 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Roberto Pili: archived-pipeline peers nationwide
Peers matched on 3 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Roberto Pili sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 3 archived trials
- 10xBio · 3 trials · 0% recruiting
- 22nd Century Group · 3 trials · 0% recruiting
- AA Secord · 3 trials · 0% recruiting
- AAADRS Clinical Research Center · 3 trials · 0% recruiting
Sponsors with similar archive density (± trial count)
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
- 3 Waves Wellness · 0% recruiting · 2 trials
- 3EO Health · 0% recruiting · 2 trials
Related
What to do with this Roberto Pili page
3 registered trials is a research-attention snapshot, not an endorsement of Roberto Pili or any single study.
- None of Roberto Pili's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Renal Cell Carcinoma is the condition Roberto Pili studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Renal Cell Carcinoma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Roberto Pili pipeline card: 3 registered trials from official public datasets.Report a data error.